Home » Protea Licenses Cardiovascular Biomarker Tech from Hopkins

Protea Licenses Cardiovascular Biomarker Tech from Hopkins

Jul 21, 2009

NEW YORK (GenomeWeb News) – Protea Biosciences has licensed technology from Johns Hopkins University that it plans to use to develop tools for improving treatment of myocardial ischemia, the company said today.

The company has licensed technology developed in the lab of Hopkins researcher Jennifer Van Eyk that has been used to identify proteins bound to human serum albumin that are associated with cardiovascular disease.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

Here We Are Again

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

In the Pink

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

All Tied Up in a Bow

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

This Week in PNAS

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.

What's Popular?

In Proteomics & Protein Research

  1. Pan-Cancer Mutation Study Identifies Protein Kinases Key to Tumor Suppression

    Premium

  2. Freenome, Biognosys Partner on Early Cancer Detection

  3. Copenhagen Team IDs Protein Complex Key to DNA Damage Repair

    Premium

  4. Top Down Proteomics Identifies Protein-Level Effects of KRAS Mutations in Colorectal Cancer

    Premium

  5. Waters Q1 Revenues Up 7 Percent

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.